Mirxes

To know is to Act.

Headquartered in Singapore, Mirxes is one of the world’s foremost biotechnology companies, empowered by miRNA to improve and save lives through early detection. We discover, develop, and deliver accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases, and make them accessible to all.

01/09/2026

𝐌𝐢𝐫𝐱𝐞𝐬 𝐨𝐛𝐭𝐚𝐢𝐧𝐬 𝐇𝐒𝐀 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐟𝐨𝐫 𝐢𝐭𝐬 𝐟𝐢𝐫𝐬𝐭 𝐜𝐨𝐧𝐬𝐮𝐦𝐞𝐫-𝐟𝐚𝐜𝐢𝐧𝐠 𝐡𝐨𝐦𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐭𝐞𝐬𝐭

We are thrilled to announce that our at-home colorectal cancer screening kit, FITRAPID™⁠, has officially received approval from Singapore’s Health Sciences Authority (HSA)! This milestone marks our first consumer-facing (B2C) launch in Singapore — bringing accessible, proactive cancer screening directly to households.

With a robust product line and pipeline anchored by professional use single cancer blood tests GASTROClear™, LUNGClear™, and our upcoming multi-cancer blood test CADENCE, the FITRAPID™⁠ home test completes our cancer early detection portfolio — officially launching Mirxes into a dual-engine growth stage driven by both professional precision diagnostics and consumer-focused home screening solutions across Southeast Asia (SEA).

𝐖𝐡𝐲 𝐅𝐈𝐓𝐑𝐀𝐏𝐈𝐃™⁠?

- 𝐏𝐫𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐭 𝐇𝐨𝐦𝐞: FITRAPID™⁠ is a non-invasive, affordable, and easy-to-use at-home kit designed to detect f***l occult blood — a critical early warning sign of lower gastrointestinal tract diseases, such as colorectal cancer and polyps. By allowing individuals to complete testing without visiting a clinic, we are significantly lowering the barrier to cancer screening.

- 𝐀𝐥𝐥-𝐢𝐧-𝐨𝐧𝐞 𝐃𝐞𝐬𝐢𝐠𝐧 & 𝐑𝐚𝐩𝐢𝐝 𝐑𝐞𝐬𝐮𝐥𝐭𝐬: This user-friendly device integrates the collection stick, diluent, and testing strip into a uniquely engineered single device that significantly simplifies the operational process, greatly enhances usability and reduces the risk of contamination and user error. Results will be clearly visible in 5 to 10 minutes.

- 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐚𝐧 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐄𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦: FITRAPID™⁠ is not a standalone product — it’s the entry point to a complete diagnostic journey. In the next few months, Mirxes plans to introduce CADENCE CRC, a blood-based colorectal cancer early detection test that is the first application of our next-generation multi-omic, multi-cancer testing platform CADENCE. Together, FITRAPID™⁠ (at-home screening) and CADENCE CRC (professional lab use) create a seamless screening-to-precision testing closed loop.

Dr Zhou Lihan, Co-founder and CEO of Mirxes, said: “The synergy between FITRAPID™⁠ and our upcoming CADENCE CRC blood test represents a key move in building our integrated cancer screening solutions, starting with colorectal cancer. Combining the two lays the path for larger-scale adoption of colorectal cancer screening among the population, while creating more commercial growth opportunities for the company.”

Following approval from the HSA, FITRAPID™⁠ can now be sold through clinics, retail pharmacies, e-commerce platforms, and direct-to-consumer channels. Outside Singapore, FITRAPID™⁠ has been commercialised successfully in Thailand post Thai FDA approval and is pursuing regulatory clearance across other SEA markets.

17/07/2026

“So when we expanded into bigger teams with more processes and higher expectations from partners, we really started to see the value of adopting standards early,” Jeremiah Decosta, SVP (Operations), Mirxes.

“For us, following these standards has shaped a culture of precision and quality across the company. Because when you are dealing with medical devices, this is non-negotiable.”

13/07/2026

Watch the full version of Rewriting Cancer - The Mirxes Story, produced by BBC StoryWorks, at www.mirxes.com!

09/07/2026

❤️ Family Day 2026: Making Memories Together! ❤️

We were thrilled to host our very first Family Day! Thank you to everyone who joined us and brought so much joy, energy, and laughter to the event.

Creating meaningful connections and sharing wonderful memories with both colleagues and their families is what makes our community so special!

01/07/2026

"For the first time, we showed that a blood test can be nearly as accurate as an endoscope, and it detects 87.5% of Stage 1 stomach cancer. So it is a game-changer, in terms of elevating blood-based cancer early detection... Hopefully in 3 to 5 years time we're able to shift Asia's stomach cancer diagnosis from 70% diagnosed late to 70% diagnosed early." – Dr Zhou Lihan, Co-Founder and CEO, .

. Watch the Mirxes story in the latest series of , a globally acclaimed series commissioned by Union for International Cancer Control (UICC) and produced by BBC StoryWorks, below 👇. Discover and understand our journey, our mission, and our vision - together, we can advance preventive medicine and save lives through cancer early detection!

20/03/2026

Selamat Hari Raya and Eid Mubarak to all our Muslim friends!

16/03/2026

A massive shoutout to the 21 runners who ran on the National Stadium track over the weekend for the Singapore Cancer Society Relay For Life (RFL) 100KM Challenge!

Split into three teams, our colleagues pushed through a gruelling 12-hour relay to complete the 100KM together. While the heat and humidity of Singapore made every KM a mental and physical battle, we kept one thought at the forefront: the discomfort of a long-distance run is nothing compared to the journey cancer patients endure every day.

At its heart, RFL celebrates life and the courage of cancer survivors. It is a powerful reminder that when a community rallies together, we can provide the support and funding needed for change.

At Mirxes, our mission is clear: to save lives through early, actionable, and personalised diagnoses. Every KM covered by our team represents our unwavering commitment to this goal. We don’t just work in labs or offices; we are part of a global effort to change the narrative of cancer from one of fear to one of hope through early detection.

Thank you to our runners for representing the Mirxes spirit and to everyone who supported the cause. Together, we keep moving forward!

16/02/2026

Wishing everyone a Year of the Horse defined by continued momentum, meaningful impact, and new heights!

06/02/2026

Fifteen laptops, a group of passionate youths, and a community space in Bukit Gombak. Last Monday evening was not just about hardware refurbishment, but a simple reminder of the impact technology can have when people come together with a purpose.

At , we believe our influence should extend beyond our labs and offices, reaching into the heart of the community. Alongside the Eagles Interact youth group from Bukit Gombak, tech volunteers from Mirxes rolled up their sleeves to give these laptops a second lease of life. Our key message on the ground was “Gift ‘IT’ Forward” — we are focused on digital dignity and encouraging others to do more for their communities, rather than simply passing on old equipment.

Care was taken to properly wipe, reinstall, test, and pack each unit. We wanted to ensure that when these laptops reach their new owners, they arrive not as hand-me-downs, but as tools ready to be used with confidence. This event also marked the launch of a wider Mirxes CSR initiative to refurbish and donate 100 laptops over the next six months as part of our ongoing tech refresh.

The presence of Ms Low Yen Ling, Senior Minister of State for Trade and Industry and Culture, Community and Youth, and Grassroots Adviser (Bukit Gombak), added a meaningful dimension to the session. She spent time observing the team in action and spoke about how this initiative can potentially grow into more opportunities for the youths, including visits, mentorships and internships at Mirxes in the months ahead.

Perhaps the most memorable part of the evening was the spirit of “reverse mentoring”. Working alongside the youths, it became clear that the learning flowed both ways. What unfolded was not just an act of giving, but a genuine collaboration between two generations of tech-driven minds.

In the end, the value of the evening went far beyond the laptops themselves. It was about the heart — a reminder that when time and care are invested, even a small act can carry a much deeper meaning for the community we are part of.

22/01/2026

is starting 2026 by expanding our footprint in Thailand!

We just signed a strategic partnership with N Health, a member of the Bangkok Dusit Medical Services (BDMS) Group, Thailand’s largest private healthcare provider. This collaboration marks a pivotal development in our mission to democratize cancer screening in Thailand by integrating Mirxes’ world-leading microRNA (miRNA) cancer screening solutions into N Health’s nearly 60 hospitals nationwide.

Beyond our clinical expansion, we are also excited to announce the Thailand launch of FITRapid and HELICORapid, our first-of-their-kind at-home diagnostic kits, which received Thailand’s FDA approval in October and December 2025 respectively. These direct-to-consumer tools empower individuals to take charge of their health from the privacy of their own homes. FITRapid identifies f***l occult blood, a critical early indicator of colorectal polyps or cancer, while HELICORapid is designed to detect H. pylori — the strongest known risk factor for stomach cancer.

This dual-pronged strategy is essential to meeting the rising demand in Thailand’s health check-up market, which is projected to reach US$498.7 million by 2030.

Address

Singapore
Singapore

Website

http://mirxes.com/

Alerts

Be the first to know and let us send you an email when Mirxes posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Mirxes:

Want your business to be the top-listed engineering company in Singapore?